Drug Landscape ›
Regular Insulin ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 1,157
Most-reported reactions
Blood Glucose Increased — 202 reports (17.46%) Nausea — 137 reports (11.84%) Pain — 131 reports (11.32%) Hypoglycaemia — 120 reports (10.37%) Renal Failure — 110 reports (9.51%) Blood Glucose Decreased — 100 reports (8.64%) Anxiety — 94 reports (8.12%) Vomiting — 92 reports (7.95%) Weight Decreased — 86 reports (7.43%) Injury — 85 reports (7.35%)
Source database →
Regular Insulin in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Regular Insulin approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Regular Insulin in United States?
University of Oklahoma is the originator. The local marketing authorisation holder may differ — check the official source linked above.